AAPL 222.73 -0.4559% MSFT 391.955 -0.8111% NVDA 113.445 -6.003% GOOGL 166.905 -2.1429% GOOG 169.12 -2.124% AMZN 202.04 -1.7841% META 610.7313 -2.4874% AVGO 178.775 -5.0382% LLY 835.66 -1.9581% TSLA 270.5301 -6.1116% TSM 172.12 -4.8535% V 344.51 -0.0319% JPM 251.71 0.231% UNH 517.57 0.8063% NVO 72.16 -1.9565% WMT 84.78 0.0236% LVMUY 128.17 -0.7588% XOM 118.245 1.4195% LVMHF 638.0 -1.6131% MA 548.525 0.6172%
Last update at 2025-03-26T16:48:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -25.91500M | -22.73400M | -9.68100M | -9.12500M | -8.62500M |
| Minority interest | - | - | - | - | - |
| Net income | -21.19800M | -18.88700M | -8.44500M | -7.82800M | -7.28800M |
| Selling general administrative | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | 0.00588M | -4.65800M | 0.15M |
| Reconciled depreciation | 0.03M | 0.04M | 0.02M | 0.02M | 0.03M |
| Ebit | -27.65600M | -22.93800M | -10.63600M | -9.68100M | -9.48700M |
| Ebitda | -27.88900M | -22.98200M | -10.65800M | -9.78200M | -9.45800M |
| Depreciation and amortization | -0.23300M | -0.04400M | -0.02200M | -0.10100M | 0.03M |
| Non operating income net other | - | - | -2.82000M | 0.56M | 0.92M |
| Operating income | -27.65600M | -22.93800M | -10.63600M | -9.68100M | -9.54800M |
| Other operating expenses | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M |
| Interest expense | -2.00600M | 0.29M | 1.00M | 0.68M | 0.00000M |
| Tax provision | -4.71700M | -3.84700M | -1.23600M | -1.29600M | -1.33700M |
| Interest income | 0.21M | 0.02M | 0.04M | 0.22M | 0.33M |
| Net interest income | 0.21M | 0.02M | 0.04M | 0.22M | 0.33M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -4.71700M | -3.84700M | -1.23600M | -1.29700M | -1.33700M |
| Total revenue | 0.00000M | 0.00000M | 0.00588M | 0.00000M | 0.15M |
| Total operating expenses | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M |
| Cost of revenue | - | - | - | 4.66M | 4.33M |
| Total other income expense net | 1.74M | 0.20M | 0.95M | 0.56M | 0.59M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -21.19800M | -18.88700M | -8.44500M | -7.83000M | -7.28800M |
| Net income applicable to common shares | -21.39900M | -19.08800M | -8.64600M | -8.03100M | -7.48900M |
| Preferred stock and other adjustments | - | - | 0.20M | 0.20M | 0.20M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 8.80M | 27.50M | 42.59M | 36.80M | 15.31M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.13M | 6.07M | 0.08M | 0.07M | 0.10M |
| Total liab | 8.20M | 11.99M | 5.32M | 3.54M | 3.61M |
| Total stockholder equity | 0.61M | 15.51M | 37.26M | 33.26M | 11.70M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 4.62M | 4.83M | 3.18M | 1.97M | 1.53M |
| Common stock | 0.00100M | 4.50M | 0.01000M | 0.00600M | 0.02M |
| Capital stock | 0.00100M | 4.50M | 0.01000M | 0.00600M | 0.02M |
| Retained earnings | -428.28200M | -406.15700M | -384.95900M | -366.07200M | -357.62700M |
| Other liab | - | 4.49M | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 2.92M | 1.55M | 0.00123M | - |
| Cash | 3.38M | 18.34M | 36.56M | 33.41M | 11.88M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 8.16M | 7.39M | 5.29M | 2.49M | 2.42M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -3.34100M | -18.23900M | -36.52900M | -32.34900M | -10.69400M |
| Short term debt | - | - | - | 0.09M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.04M | 0.11M | 0.03M | 1.06M | 1.19M |
| Other stockholder equity | 429.80M | 418.48M | 422.96M | 400.07M | 370.13M |
| Property plant equipment | - | 0.17M | 0.09M | 0.11M | 0.03M |
| Total current assets | 7.44M | 24.41M | 40.94M | 35.47M | 14.02M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 15.51M | 37.26M | 33.26M | 11.70M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.93M | 5.64M | 3.73M | 1.31M | 1.33M |
| Long term debt | - | - | - | - | - |
| Inventory | - | -5.64000M | 0.58M | 0.68M | 0.70M |
| Accounts payable | 3.54M | 2.56M | 2.12M | 0.51M | 0.89M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.90800M | -1.31600M | -0.74800M | -0.74600M | -0.81900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00600M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -366.07200M | -357.60000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.26M | 2.92M | 1.55M | 1.23M | 1.26M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.36M | 3.09M | 1.65M | 1.33M | 1.29M |
| Capital lease obligations | 0.04M | 0.11M | 0.03M | 1.06M | 1.19M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.00600M | -0.00700M | -0.02700M | -0.09600M | 0.03M |
| Change to liabilities | - | 2.58M | 2.91M | 0.03M | -2.20800M |
| Total cashflows from investing activities | - | -0.00700M | -0.02700M | -0.09600M | 0.03M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 0.85M | 3.00M | 21.74M | 29.50M | 3.85M |
| Change to operating activities | - | -3.78400M | -3.93100M | 0.12M | 0.21M |
| Net income | -22.55500M | -21.19800M | -18.88700M | -8.44500M | -7.83000M |
| Change in cash | -14.96700M | -18.21400M | 3.15M | 21.52M | -5.61900M |
| Begin period cash flow | 18.34M | 36.56M | 33.41M | 11.88M | 17.50M |
| End period cash flow | 3.38M | 18.34M | 36.56M | 33.41M | 11.88M |
| Total cash from operating activities | -16.11200M | -20.82700M | -18.54000M | -7.93400M | -9.44700M |
| Issuance of capital stock | 0.09M | 3.20M | 17.37M | 25.16M | - |
| Depreciation | 0.03M | 0.03M | 0.04M | 0.02M | 0.02M |
| Other cashflows from investing activities | - | - | - | - | 0.04M |
| Dividends paid | 0.20M | 0.20M | 0.20M | 0.20M | 0.20M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | - | - | - | 29.70M | 4.05M |
| Other cashflows from financing activities | 1.05M | -0.00700M | 4.57M | -0.09600M | 0.03M |
| Change to netincome | - | 1.55M | 1.33M | 0.43M | 0.43M |
| Capital expenditures | 0.00600M | 0.00700M | 0.03M | 0.10M | 0.01000M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | 0.03M | 0.14M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | 21.47M | -5.57100M |
| Change in working capital | 5.01M | -1.16700M | -0.85300M | 0.06M | -2.06500M |
| Stock based compensation | 1.47M | 1.51M | 1.16M | 0.43M | 0.47M |
| Other non cash items | 1.17M | -0.96700M | -3.51800M | -21.32500M | -0.03800M |
| Free cash flow | -16.11800M | -20.83400M | -18.56700M | -8.03000M | -9.45700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CYCC Cyclacel Pharmaceuticals Inc |
0.005 1.67% | 0.30 | - | - | 5.52 | 3.82 | 6.10 | 0.04 |
| NVO Novo Nordisk A/S |
-1.44 1.96% | 72.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.28 1.75% | 72.07 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-7.84 1.54% | 501.20 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.08 0.01% | 634.22 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
200 Connell Drive, Berkeley Heights, NJ, United States, 07922
| Name | Title | Year Born |
|---|---|---|
| Mr. Spiro George Rombotis | Pres, CEO & Exec. Director | 1959 |
| Mr. Paul McBarron | Exec. VP of Fin., CFO, COO, Sec. & Exec. Director | 1961 |
| Dr. Mark H. Kirschbaum M.D. | Sr. VP & Chief Medical Officer | 1961 |
| Ms. Gill Christie | Director of HR | 1957 |
| Dr. Robert Westwood Ph.D. | Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. | 1944 |
| Mr. Spiro George Rombotis | President, CEO & Executive Director | 1959 |
| Mr. Paul McBarron | Executive VP of Finance, CFO, COO, Secretary & Executive Director | 1961 |
| Ms. Gill Christie | Director of Human Resources | 1957 |
| Dr. Brian Schwartz M.D. | Interim Chief Medical Officer & Director | 1963 |
| Grace Kim | Investor Relations Executive | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
AU
UK
CA
NZ
Please wait processing your request...